Zomedica Corp. (OTCQB: ZOMDF) is an animal health company that develops and markets diagnostic and therapeutic products for companion animals, including dogs, cats, and horses. Revenue comes from product sales of devices and consumables across its portfolio of diagnostic instruments and therapeutic systems sold to clinical veterinarians. Zomedica operates as a development-stage company and has not achieved profitability, reporting a net loss of $81,786 thousand for the year ended December 31, 2025, and an accumulated deficit of $299,773 thousand as of December 31, 2025. The company holds 57 issued U.S. patents and 100 issued international patents as of the filing date of March 16, 2026. Corporate headquarters are in Ann Arbor, Michigan, with a manufacturing and distribution center in Roswell, Georgia. Zomedica relies on third-party suppliers and developmental partners for component manufacturing.
TRUFORMA diagnostic platform, TRUVIEW imaging product line, VETGuardian PLUS patient monitoring system, Assisi Loop and Assisi Calmer Canine pain and anxiety products, VETIGEL wound care product, and shock wave therapy devices including the X-Trode handpiece for companion animals and equines.
Product sales of veterinary diagnostic and therapeutic devices and associated consumables to clinical veterinarians. Revenue is transactional. Certain product lines, including the Assisi Loop, VETIGEL, and VETGuardian PLUS, are built on licensed intellectual property from third-party partners.
Clinical veterinarians treating companion animals including dogs, cats, and horses. End markets include small animal veterinary practices and equine veterinary care.
Primary operations in the United States, headquartered in Ann Arbor, Michigan, with a manufacturing and distribution center in Roswell, Georgia. Holds international patents in various countries. Common shares trade on the OTCQB Market under the symbol ZOMDF, with trading commencing March 5, 2025.
Loading...